Hikma Pharmaceuticals PLC (HIK.L)
|Market Cap (Mil.):||£2,321.22|
|Shares Outstanding (Mil.):||197.76|
NEW YORK, Nov 20 - Unilife Corp : * Up 21.4 percent to $3.40 in premarket; reaches supply deal with Hikma Pharmaceuticals
Nov 20 - Hikma Pharmaceuticals PLC : * Signed a long term commercial supply contract with Unilife Corporation * Signs long term supply agreement with Unilife * Deal for the use of Unifill prefilled syringes with a range of generic
Nov 8 - Hikma Pharmaceuticals Plc said it expects full-year revenue growth of 20 percent and raised its sales forecast for its generics unit as sales of antibiotic doxycycline continued to soar.
LONDON, Sept 18 - Jordan's Hikma Pharmaceuticals has formed a joint venture with Sheikh Mohammed Hussein Al Amoudi's MIDROC Group to enter the Ethiopian healthcare market, where health spending is likely to more than double in the next few years.
Aug 21 - Hikma Pharmaceuticals raised its full-year revenue forecast for the third time in four months, riding on strong sales of generic antibiotic doxycycline, a drug used to prevent and treat malaria and other infections.
Aug 21 - Hikma Pharmaceuticals said it expected full-year revenue to rise 20 percent as strong sales of its generic antibiotic doxycycline in the United States continue and reported a 93 percent jump in first-half profit.
* Shares up as much as 9 pct (Adds analysts' comments, details; updates share movement)
LONDON, July 1 - Hikma Pharmaceuticals PLC : * Signing of an exclusive commercialisation agreement with theravance, inc for
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Hikma Pharmaceuticals PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: Directors Deals Ltd.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.